Immunogenicity, Reactogenicity and Safety of a Combined DTPa-IPV Vaccine Compared with Separate DTPa and IPV Vaccines in Healthy Korean Infants

  title={Immunogenicity, Reactogenicity and Safety of a Combined DTPa-IPV Vaccine Compared with Separate DTPa and IPV Vaccines in Healthy Korean Infants},
  author={Chang Hwi Kim and Sung Ho Cha and Son Moon Shin and Chun Soo Kim and Young Youn Choi and Young Jin Hong and Myoung Jae Chey and Kwang Nam Kim and Jae Kyun Hur and Dae Sun Jo and Sunghwan Kim and Sang Lak Lee and Eun Song Song and Gunasekaran Ramakrishnan and Jin-Ju Ok and Olivier Van Der Meeren and Hans Ludwig Bock and Jung Soo Kim},
  journal={Journal of Pediatric infectious diseases},
Purpose : To compare immunogenicity and reactogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine (DTPa-IPV, IPV, GlaxoSmithKline Biologicals) with co-administration of commercially available DTPa and IPV vaccines at separate injection sites (DTPa+IPV). Methods : A total of 458 infants aged 8-12 weeks were randomized to receive three-ose primary vaccination at 2, 4 and 6 months with DTPa-IPV or DTPa+IPV. Blood samples were collected pre and post… 

Figures and Tables from this paper

Post-marketing surveillance to assess the safety and tolerability of a combined diphtheria, tetanus, acellular pertussis and inactivated poliovirus vaccine (DTaP-IPV) in Korean children
Data from this post-marketing surveillance (PMS) indicate that DTaP-IPV has an acceptable safety profile when given to Korean children in accordance with local prescribing recommendations in routine childhood immunization.
Safety and reactogenicity of the combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b (DTPa-IPV/Hib) vaccine in healthy Vietnamese toddlers: An open-label, phase III study
DTPa-IPV/Hib conjugate vaccine was well tolerated as a booster dose in healthy Vietnamese children aged <2 years and pain was the most frequent grade 3 local symptom.
Comparison of the Immunogenicity and Safety of Three Enhanced Inactivated Poliovirus Vaccines from Different Manufacturers in Healthy Korean Infants: A Prospective Multicenter Study
The currently used inactivated poliovirus vaccines was demonstrated to be safe and immunogenic in healthy Korean infants and local and systemic adverse events were reported throughout the study.


Comparative reactogenicity and immunogenicity of booster doses of diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine and diphtheria-tetanus-inactivated poliovirus vaccine in preadolescents.
To prevent recent resurgence of pertussis in France, this vaccine should be preferred as the booster dose of DTPa-IPV at 11 to 13 years of age as recently approved by the National Council of Hygiene of France.
Diphtheria-Tetanus-Acellular Pertussis and Inactivated Poliovirus Vaccines Given Separately or Combined for Booster Dosing at 4–6 Years of Age
The combined DTaP-IPV vaccine provided immunogenicity and reactogenicity that is comparable to separately administered diphtheria-tetanus-acellular pertussis and IPV vaccines, with the advantage of requiring one less injection.
A fourth dose of DTPa-IPV vaccine given to 4–6 year old children in Italy and Sweden following primary vaccination at 3, 5 and 11–12 months of age
The combined DTPa-IPV vaccine could be used to add DTP valences to the IPV vaccine currently given to children in Scandinavia and Italy at 4–6 y of age and reinforce protection against 4 diseases.
Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus- inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections.
Both administrations of the candidate vaccine were found to be safe, immunogenic, and well tolerated and have the potential to simplify childhood immunization.
Comparative study of the reactogenicity of a three-component acellular pertussis vaccine and whole-cell pertussis vaccine administered to healthy Singaporean infants.
  • L. Shek, E. Khor, B. Lee
  • Medicine, Biology
    The Southeast Asian journal of tropical medicine and public health
  • 2003
It was found that GSK Biologicals' DTPa vaccine was significantly less reactogenic as compared to the locally used DTPw vaccine manufactured by Commonwealth Serum Laboratories when administered as a 3-dose primary vaccination course to healthy infants at the age of 3, 4 and 5 months in Singapore.
Kinrix™: a new combination DTaP–IPV vaccine for children aged 4–6 years
Clinical trials have shown Kinrix to be immunogenic in 4–6-year-old children, with a safety profile comparable with that of separate DTaP and IPV vaccination.
A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
The two acellular DTP vaccines studied were safe, immunogenic, and efficacious against pertussis, whereas the efficacy of the whole-cell DTP vaccine was unexpectedly low.